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We administered hepatic arterial infusion chemotherapy (HAIC) prior to FOLFOX to three patients 
with unresectable liver metastases from colorectal cancer.  The patientsʼ disease state was found to be 
highly advanced based on both computed tomography ﬁndings and liver function tests.  The treatment 
strategy included an initial administration of HAIC to control liver metastases and improve liver func-
tion in order to facilitate the subsequent safe administration of FOLFOX without drug loss.  As the 
HAIC regimen,  1,000mg/m2 of 5-FU was administered weekly by continuous 5-h infusion after per-
forming laboratory investigations through an implanted port-catheter system.  After 3 HAIC cycles 
administered over 3 consecutive weeks,  the mean alkaline phosphatase levels decreased from 
969.3IU/l to 422IU/l due to shrinkage of the liver metastases.  Thereafter,  FOLFOX without drug loss 
could be safely initiated for all patients.  Two patients succumbed 488 and 333 days after HAIC was 
initiated; the third patient is still alive and has been followed-up for 1215 days.  The combined use of 
HAIC and standard systemic chemotherapy could be a feasible and eﬃcacious treatment in highly 
advanced cases of liver dysfunction.
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ystemic chemotherapy is usually the preferred 
treatment for unresectable liver metastases 
from colorectal cancer [1].  With recent advances in 
new drugs and the standardization of chemotherapy 
regimens for colorectal cancer,  patient survival has 
been prolonged.  Currently,  FOLFOX (5-ﬂuorouracil 
(5-FU)/leucovorin with oxaliplatin) and FOLFIRI 
(5-FU/leucovorin with irinotecan) are used as stan-
dard chemotherapy regimens [1,  2],  and the median 
survival with these regimens is reported to be 20.6-
21.5 months [2].  The addition of bevacizumab to these 
regimens further prolongs the survival [3].  However,  
in patients with highly advanced unresectable liver 
metastases,  it is vital but very diﬃcult to select the 
initial treatment regimen because it is often impossible 
to perform further treatment if the initial treatment 
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fails.  Fakih MG has reported that three patients with 
metastatic colon cancer and severe liver dysfunction 
were treated by FOLFOX [4].  After the initial 
improvement in disease status,  disease progression 
was noted in 2 patients at 4 and 7 months from the 
inception of therapy,  while treatment was ongoing in 
the third patient at 5 months.
　 Repeated hepatic arterial infusion chemotherapy 
(HAIC) through an implanted port-catheter system is 
an eﬀective therapy for unresectable liver metastases 
from colorectal cancer [5-7].  Compared to systemic 
chemotherapy,  HAIC increases the possibility of 
tumor response and might improve liver function by 
shrinking liver metastases [7-10]; however,  a com-
parison was not made between HAIC with FOLFOX 
and HAIC with FOLFIRI in those reports.  The 
administration of high doses of 5-FU,  which is used as 
an HAIC regimen in Japan,  is particularly associated 
with a good tumor response and patient-survival rates,  
and has fewer and less severe adverse events [5,  11].
　 We administered HAIC prior to FOLFOX to 3 
patients with highly advanced unresectable liver 
metastases from colorectal cancer; further treatment 
in the event of failure of the initial treatment was 
considered impossible in these patients.  The treat-
ment strategy involved an initial administration of 
HAIC to control liver metastases and improve liver 
function in order to facilitate the subsequent safe 
administration of FOLFOX without drug loss.  This 
strategy was formulated on the basis of the high 
tumor-response rate and the fewer and less severe 
adverse eﬀects associated with HAIC.
Case Report
　 This report was approved by our institutional 
review board,  and written informed consent was 
obtained from each patient.
　 Between November 2006 and April 2007,  69 
patients were admitted to undergo initial therapy for 
colorectal cancer at our institution.  Of those patients,  
three consecutive patients (2 men and 1 woman; mean 
age,  56.0 years) had highly advanced synchronous 
liver metastases.  In all three patients,  liver metasta-
ses were judged to be unresectable due to liver dys-
function and multiple metastases in both the right and 
left lobes of the liver.  The primary cancer sites were 
the descending colon (n＝1),  sigmoid colon (n＝1),  
and rectum (n＝1).  The patient characteristics are 
shown in Table 1.
　 Our treatment strategy was as follows.  First,  
surgical resection of primary colorectal cancer was 
performed.  Next,  we repeatedly administered HAIC 
through an implanted port-catheter system as the ini-
tial treatment for liver metastases,  considering our 
patientsʼ advanced state of disease,  as indicated by 
both the computed tomography (CT) ﬁndings (Aquilion 
64; Toshiba,  Tokyo,  Japan) and the results of liver 
function tests.  As the HAIC regimen,  1,000mg/m2 of 
5-FU was administered weekly by continuous 5-h infu-
sion after performing laboratory investigations [5].  
The levels of alkaline phosphatase (ALP) were more 
than 2.5 times the upper limit of normal (ULN;  
875IU/l) due to the liver metastases; thus,  this value 
was used as an index for HAIC continuation.  HAIC 
was administered weekly to control the liver metasta-
ses until the ALP levels were within 1.5 times the 
ULN (525IU/l).  Thereafter,  FOLFOX without drug 
loss was started.
　 The patients underwent curative surgical resection 
of primary colorectal cancer and lymph node metasta-
ses.  Metastases in N1 lymph nodes were observed in 
2 patients; 1 patient showed N2 lymph node metasta-
ses.  Extrahepatic metastases in the lung,  bone,  brain,  
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Liver Function before starting HAIC/after HAIC
Tumor Marker before
starting HAIC/after HAIC
Liver Metastases Volume 
(%)§ before starting 





ALP (IU/l) LDH (IU/l) AST (IU/l) ALT (IU/l) T-BIL (mg/dl) CEA CA19-9
1 58/F D-colon 971/349   710/303 37/23 27/8 0.4/0.5 3,258.9/389.3 11,184/1,302 42.8/33.9   333 Dead
2 55/M S-colon 927/401 1,045/312 59/27 54/27 0.4/0.4   65.4/42.1   70/56 53.6/45.2 1,215 Alive
3 55/M rectum 1,010/516   714/303 32/22 26/22 0.7/0.6   92.8/23.6   13/1.4 31.9/22.3   488 Dead
D-colon,  descending colon; S-colon,  sigmoid colon; HAIC,  hepatic arterial infusion chemotherapy; ALP,  alkaline phosphatase; LDH,  lactate dehydrogenase; AST,  
aspartate aminotransferase; ALT,  alanine aminotransferase; T-BIL,  total bilirubin.  §Liver metastases volume (%) was esitmated using the following formula: 
liver metastases volume (ml)/[normal liver parenchymal volume (ml)＋ liver metastases volume (ml)]×100.
and peritoneum were not observed in the patients.
　 Radiological placement of the port-catheter system 
was performed at 14,  20,  and 21 days after surgery 
(Fig.  1).  All placement procedures were performed in 
an angiography suite under local anesthesia.  Prior to 
catheter placement,  the patients underwent angiogra-
phy and arterial embolization to allow arterial mapping 
and prevent extrahepatic inﬂux of 5-FU; these proce-
dures were performed using a 4-French angiographic 
catheter (Clinical Supply,  Gifu,  Japan) that was 
inserted from the left femoral artery.  The extrahe-
patic arteries that branched from the hepatic artery 
such as the right gastric artery and the posterior 
superior pancreatoduodenal artery were embolized 
with microcoils (Truﬁll; Cordis,  Miami Lakes,  FL,  
USA) through a 2.1-French microcatheter (Sniper 
2; Clinical Supply) inserted coaxially.  Next,  a 
4-French angiographic catheter was inserted from the 
right femoral artery and advanced to the common 
hepatic artery via the celiac artery.  An indwelling 
catheter (W spiral catheter; PIOLAX,  Yokohama,  
Japan) with a side hole was then inserted using the 
catheter-exchange method.  The catheter tip was 
inserted into the gastroepiploic artery such that the 
side hole was placed in the common hepatic artery.  
The gastroepiploic artery around the tip of the 
indwelling catheter was embolized using microcoils 
through a microcatheter inserted coaxially via the 
angiographic catheter inserted from the left femoral 
artery.  Finally,  the proximal end of the indwelling 
catheter was connected to a port implanted in the 
subcutaneous pocket created in the right thigh.  No 
complications such as hematoma,  infections,  and 
hepatic artery injuries and occlusions occurred during 
or after the procedure.
　 On the following day,  digital subtraction angiogra-
phy and CT were performed during injection of a 
contrast medium through the implanted port-catheter 
system to conﬁrm that the catheter was not dislodged 
and to ensure that the entire liver was perfused ade-
quately [12].  Thereafter,  HAIC was administered 
through the port-catheter system.  After the adminis-
tration of 5-FU,  this system was ﬂushed and ﬁlled 
with 2ml heparin solution (1,000IU/ml).  The results 
of the liver function tests of the patients before start-
ing HAIC were as follows: mean ALP,  969.3IU/l;  
mean lactate dehydrogenase (LDH),  823IU/l; mean 
aspartate aminotransferase (AST),  42.7IU/l; mean 
alanine aminotransferase (ALT),  35.7IU/l; and mean 
total bilirubin (T-BIL),  0. 5mg/dl (Table 1).  In all 
patients,  the percentage of liver involvement with 
metastases exceeded 30ｵ (mean,  42.8ｵ),  as deter-
mined using contrast-enhanced CT and a workstation 
(Ziostation; Ziosoft,  Tokyo,  Japan).
　 After starting HAIC,  no adverse events were 
observed in any of the patients.  The ALP levels and 
other liver function parameters decreased to＜1.5 
times the ULN after 3 HAIC cycles administered 
over 3 consecutive weeks (Table 1).  The results of the 
liver function tests performed after HAIC administra-
tion were as follows: mean ALP,  422IU/l; mean 
LDH,  306IU/l; mean AST,  24IU/l; mean ALT 
19IU/l; and mean T-BIL,  0.5mg/dl.  Though three 
patients had stable disease,  according to RECIST 
criteria [13],  on contrast-enhanced CT,  the percent-
age of liver involvement with metastases decreased 
(mean,  33.8ｵ) (Fig.  2).  Thereafter,  FOLFOX with-
out drug loss could be safely initiated for all patients,  
and the chemotherapy regimen was changed to 
FOLFIRI after FOLFOX had failed.
　 FOLFOX and FOLFIRI were administered a total 
of 12 times in case 1 and 11 times in case 3,  respec-
tively.  The systemic chemotherapy failed to produce 
a positive response in these patients and could not be 
continued.  Their performance status worsened be - 
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Fig. 1　 Arteriogram via port shows that all hepatic arteries are 
well-visualized.  The catheter tip is inserted into the gastroepiploic 
artery (arrow).  The side hole is placed into the common hepatic 
artery (small arrowhead).  To prevent an extrahepatic inﬂux of anti-
cancer agents,  the gastroduodenal artery (arrowhead) and right 
gastric artery (small arrow) are embolized with microcoils.
cause their liver metastases progressed; HAIC was 
therefore readministered to both patients (16 times for 
one patient and 6 times for the other).  The case 1 
patient succumbed to the disease 488 days after HAIC 
was initiated: case 3 succumbed after 333 days.
　 In case 2,  FOLFOX and FOLFIRI were adminis-
tered a total of 24 times.  Afterward,  another sys-
temic chemotherapy was administered because he 
failed to respond to these treatment regimens.  At 
present,  he is still alive and has been followed-up for 
1215 days.
Discussion
　 HAIC for unresectable liver metastases from col-
orectal cancer was evaluated in 3 diﬀerent meta-anal-
yses [8-10]; compared with systemic chemotherapy,  
HAIC was associated with a superior response rate,  
but it did not improve patient survival.  Conversely,  in 
Japan,  it has been reported that the response rate of 
patients to HAIC is 78ｵ,  and the median survival 
time is 25.8 months after intermittent HAIC with high 
doses of 5-FU [5].  It seems that these positive 
results were an outcome of a number of contributing 
factors,  including appropriate techniques for port-
catheter system placement and evaluation of drug 
distribution using CT during arteriography [5,  12].  
Additionally,  this regimen has the advantage of being 
considerably cheaper than the current standard sys-
temic chemotherapy and usually has fewer and less 
severe adverse events than systemic chemotherapy 
[5].
　 On the basis of its superior tumor response and the 
possibility of improved liver function,  HAIC was 
administered prior to systemic chemotherapy in order 
to treat advanced unresectable liver metastases.  
HAIC was useful because it improved liver function in 
our patients by shrinking liver metastases and enabling 
the safe administration of standard systemic chemo-
therapy without drug loss.  A positive relationship 
between dose intensity and response rate has been 
documented in the treatment of advanced colon can-
cers [14]; therefore,  a lower prospective tumor 
response and a shorter prospective survival may be 
expected with the administration of chemotherapy with 
drug loss from the start of treatment.
　 In all our patients,  because the ALP levels had 
already been elevated to more than 2.5 times the ULN,  
HAIC was continued until this level was within 1.5 
times the ULN; this ALP value (ｧ2.5 times the 
ULN) came under grade 2 of the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events,  version 3.0.  Elevated ALP (ｧ2 times the 
ULN) is one of the factors associated with poor prog-
nosis in metastatic colorectal cancer patients treated 
with 5-FU,  oxaliplatin,  or oxaliplatin [15,  16].  In 
our patients,  the mean ALP levels decreased from 
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Fig. 2A　 A 58-year-old woman with multiple liver metastases 
from cancer of the descending colon.  Contrast-enhanced CT image 
obtained before the initiation of HAIC showing multiple unresect-
able liver metastases in both the right and left lobes of the liver.
Fig. 2B　 Contrast-enhanced CT image obtained after 3 HAIC 
cycles showing smaller liver metastases.  The percentage of liver 
involvement with metastases improved from 42.8% to 33.9%.
969.3IU/l to 422IU/l due to shrinkage of the liver 
metastases after only 3 consecutive HAIC cycles.  
Standard systemic chemotherapy was initiated after 
the HAIC-mediated improvement in liver function 
because the abovementioned meta-analysis evaluation 
revealed that HAIC does not improve patient survival 
over that achieved with systemic chemotherapy [8- 
10].  
　 It might have been possible to safely initiate sys-
temic chemotherapy in our patients without prior 
HAIC.  However,  if standard systemic chemotherapy 
had failed because it could not be completed (e.g.,  
incomplete administration or administration with drug 
loss),  further treatment might have been impossible 
because of the progression of advanced liver metasta-
ses.  The combined use of HAIC and standard systemic 
chemotherapy in patients with highly advanced liver 
metastases seems to eﬀectively facilitate the adminis-
tration of subsequent systemic chemotherapy without 
drug loss.  In order to prove that our treatment strat-
egy may be a viable treatment option for such patients,  
it is necessary to accumulate more cases in multi-
center and to determine the success rates and/or 
responses as well as possible adverse events.
　 In conclusion,  we safely administered FOLFOX 
without drug loss in 3 patients with highly advanced 
unresectable liver metastases from colorectal cancer 
after the improvement in liver function caused by the 
shrinkage of liver metastases due to prior HAIC.  
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